Acelot Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Acelot is a biotechnology company focused on diseases driven by functional protein misfolding, with the aim of restoring normal protein homeostasis. Its platform identifies small molecules capable of reestablishing proper folding and function, supported by proprietary assays. The scope covers disorders including ALS, FTD, Parkinson’s disease, diabetes, and cancer, and the company is based in South San Francisco, California. ACE-2223 is the lead development candidate, described as an orally bioavailable small molecule that targets misfolded TDP-43 to restore functional TDP-43 across relevant diseases. It reportedly shows brain penetrance and favorable pharmacokinetic properties and was slated for IND-enabling studies in 2024. The platform was developed by UCSB Computer Science Professor Dr. Ambuj Singh, and the company maintains a broader discovery pipeline across multiple indications.